---
title: "Anup Malleables Ltd (506087) — Share Price, Financials & Analysis"
symbol: "506087"
company: "Anup Malleables Ltd"
canonical: "https://tapetide.com/stocks/506087"
isin: "INE188O01016"
bse_code: "506087"
sector: "Industrials"
industry: "Industrial Products"
generated_at: "2026-09-13T19:17:20.580Z"
---

# Anup Malleables Ltd (506087)

Canonical page: https://tapetide.com/stocks/506087

## Company

- **BSE Code:** 506087
- **ISIN:** INE188O01016
- **Sector:** Industrials
- **Industry:** Industrial Products
- **Macro Sector:** Industrials
- **Stock Type:** EQUITY
- **Listed Since:** 2014-03-13
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** anupmalleables.com

## About

Anup Malleables manufactures bogie frame assembly, bolster assembly, cast iron, magnet frame and steel castings.

## Latest Price

## Key Insights

### Strengths

- Stock is trading at 0.54 times its book value
- Debtor days have improved from 106 to 69.6 days.

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of -1.34% over last 3 years.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| net income growth | 523% | 13% | 7% |
| revenue growth | -14% | 13% | 20% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 7.92 | 8.69 | 8.4 | 8.93 | 22.37 | 10.68 | 15.1 | 11.01 | 7.66 | 10.21 | 20.97 | 11.99 |
| Expenses | 6.84 | 7.71 | 7.22 | 7.89 | 20.64 | 10.75 | 13.64 | 10.31 | 5.16 | 8.77 | 16.86 | 12.27 |
| Operating Profit | 1.08 | 0.98 | 1.18 | 1.04 | 1.73 | -0.07 | 1.46 | 0.7 | 2.5 | 1.44 | 4.11 | -0.28 |
| OPM % | 13.64 | 11.28 | 14.05 | 11.65 | 7.73 | -0.66 | 9.67 | 6.36 | 32.64 | 14.1 | 19.6 | -2.34 |
| Other Income | 0.13 | 0.13 | 0.18 | 0.11 | 0.17 | 0.1 | 0.11 | 0.13 | 0.17 | 0.03 | 0.15 | 0.03 |
| Interest | 0.57 | 0.53 | 0.52 | 0.59 | 1.25 | 0.69 | 0.76 | 0.75 | 0.75 | 0.9 | 0.68 | 0.78 |
| Depreciation | 0.39 | 0.43 | 0.43 | 0.43 | 0.45 | 0.38 | 0.38 | 0.38 | 0.34 | 0.34 | 0.34 | 0.34 |
| Profit before tax | 0.25 | 0.15 | 0.41 | 0.13 | 0.2 | -1.04 | 0.43 | -0.3 | 1.58 | 0.23 | 3.24 | -1.37 |
| Tax % | 296 | 466.67 | -170.73 | 0 | 130 | -24.04 | 27.91 | -20 | 29.75 | -8.7 | -0.62 | -1.46 |
| Net Profit | -0.49 | -0.55 | 1.1 | 0.12 | -0.06 | -0.79 | 0.32 | -0.24 | 1.12 | 0.25 | 3.25 | -1.36 |
| EPS in Rs | -0.72 | -0.81 | 1.62 | 0.18 | -0.09 | -1.16 | 0.47 | -0.35 | 1.65 | 0.37 | 4.79 | -2 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 13.43 | 12.55 | 15.23 | 17.8 | 26.07 | 30.94 | 19.28 | 39.46 | 44.45 | 50.83 |
| Expenses | 11.31 | 10.58 | 13.24 | 14.85 | 23.71 | 27.14 | 22.43 | 35.66 | 39.7 | 43.06 |
| Operating Profit | 2.12 | 1.97 | 1.99 | 2.95 | 2.36 | 3.8 | -3.15 | 3.8 | 4.75 | 7.77 |
| OPM % | 15.79 | 15.7 | 13.07 | 16.57 | 9.05 | 12.28 | -16.34 | 9.63 | 10.69 | 15.29 |
| Other Income | 0.3 | 0.12 | 0.3 | 0.12 | 0.85 | 0.33 | 7.07 | 0.48 | 0.51 | 0.38 |
| Interest | 0.88 | 1.37 | 1.32 | 1.29 | 1.39 | 2.17 | 1.99 | 2.38 | 3.05 | 3.11 |
| Depreciation | 0.32 | 0.4 | 0.68 | 1.45 | 1.33 | 1.48 | 1.71 | 1.32 | 1.47 | 1.36 |
| Profit before tax | 1.22 | 0.32 | 0.29 | 0.33 | 0.49 | 0.48 | 0.22 | 0.58 | 0.74 | 3.68 |
| Tax % | 31.97 | 125 | 3.45 | 0 | 30.61 | 33.33 | 268.18 | -186.21 | 36.49 | — |
| Net Profit | 0.82 | -0.08 | 0.29 | 0.33 | 0.35 | 0.32 | -0.37 | 1.66 | 0.47 | 3.26 |
| EPS in Rs | — | -0.3 | 1.1 | 1.26 | 0.52 | 0.47 | -0.54 | 2.44 | 0.69 | 4.81 |
| Dividend Payout % | 4.57 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.75 | 0.75 | 2.63 | 2.63 | 2.63 | 6.79 | 6.79 | 6.79 | 6.79 | 6.79 |
| Reserves | 2.36 | 3.13 | 1.18 | 1.46 | 1.54 | 10.23 | 10.48 | 10.13 | 11.79 | 12.19 |
| Borrowings | 5.22 | 8.24 | 20.53 | 24.19 | 18.99 | 18.99 | 16.5 | 19.46 | 23 | 27.32 |
| Other Liabilities | 3.4 | 4.64 | 5.91 | 8.92 | 13.85 | 4.99 | 3.48 | 4.04 | 3.5 | 3.65 |
| Total Liabilities | 11.73 | 16.76 | 30.25 | 37.2 | 37.01 | 41 | 37.25 | 40.42 | 45.08 | 49.95 |
| Fixed Assets | 4 | 4.88 | 6.62 | 16.68 | 14.7 | 17.11 | 21.07 | 18.97 | 17.91 | 17.26 |
| CWIP | 0.43 | 0.58 | 10.25 | 2.62 | 2.82 | 3.36 | 0.24 | 0 | 0.15 | 0 |
| Investments | 0.16 | 0.17 | 0.07 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 7.14 | 11.13 | 13.31 | 17.9 | 19.49 | 20.53 | 15.94 | 21.45 | 27.02 | 32.69 |
| Total Assets | 11.73 | 16.76 | 30.25 | 37.2 | 37.01 | 41 | 37.25 | 40.42 | 45.08 | 49.95 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -0.04 | 1.87 | 1.36 | 0.24 | -2.29 | -7.08 | 6.84 | -7.14 | -1.01 | 1.78 |
| Cash from Investing Activity | -2.97 | -1.34 | -11.68 | -2.2 | 1.66 | -4.28 | -2.36 | 4.39 | -0.38 | -3.04 |
| Cash from Financing Activity | 3.29 | -0.39 | 11.09 | 1.9 | 0.11 | 11.38 | -4.66 | 2.75 | 1.24 | 1.26 |
| Net Cash Flow | 0.28 | 0.14 | 0.77 | -0.06 | -0.52 | 0.02 | -0.18 | 0 | -0.15 | 0 |
| Free Cash Flow | -2.95 | 0.52 | -10.45 | -2.02 | -0.76 | -11.38 | 4.43 | -3.38 | -1.46 | 1.17 |
| CFO/OP | 3 | 97 | 77 | 12 | -78 | -300 | 179 | 228 | -27 | 37 |

### Ratios

| Item | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 70.16 | 60.88 | 95.39 | 80.53 | 95.15 | 92.69 | 34.33 | 144.26 | 103.23 | 69.63 |
| Inventory Days | 824.55 | 1029.58 | 627.02 | 886.8 | 676.51 | 301.06 | 245.1 | 460.34 | 253.57 | 294.31 |
| Days Payable | 518.92 | 482.08 | 361.57 | 78.4 | 135.19 | 44.34 | 17.63 | 43.93 | 25.62 | 32.73 |
| Cash Conversion Cycle | 375.8 | 608.38 | 360.85 | 888.93 | 636.47 | 349.41 | 261.79 | 560.67 | 331.17 | 331.22 |
| Working Capital Days | 118.52 | 160.62 | 179.16 | 185.02 | 91.87 | 201.33 | 145.93 | 338.87 | 212.93 | 211.36 |
| ROCE % | 22.26 | 20.54 | 9.27 | 5.74 | 6.3 | 5.98 | 7.65 | -2.59 | 7.59 | 8.63 |

## Shareholding Pattern

### annual

| Category | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 |
| --- | --- | --- | --- | --- | --- |
| Promoters | 74.9% | 74.9% | 74.9% | 74.9% | 79.93% |
| Public | 25.1% | 25.1% | 25.1% | 25.1% | 20.07% |
| No. of Shareholders | 20 | 20 | 19 | 19 | 16 |

### Quarterly

| Category | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 74.9% | 74.9% | 74.9% | 74.9% | 74.9% | 74.9% | 74.9% | 74.9% | 74.9% | 74.9% | 74.9% | 79.93% |
| Public | 25.1% | 25.1% | 25.1% | 25.1% | 25.1% | 25.1% | 25.1% | 25.1% | 25.1% | 25.1% | 25.1% | 20.07% |
| No. of Shareholders | 20 | 20 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 16 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 0 / 7 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 532.79 | Sell |
| EMA (10) | 531.78 | Sell |
| SMA (20) | 558.9 | Sell |
| EMA (20) | 547.76 | Sell |
| SMA (50) | 581.36 | Sell |
| EMA (50) | 571.34 | Sell |
| SMA (100) | 600.1 | Sell |
| EMA (100) | 594.08 | Sell |
| SMA (200) | 632.27 | Sell |
| EMA (200) | 632.49 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 37.75 | Neutral |
| MACD (12,26,9) | -18.41 | Sell |
| Stochastic (14,3,3) | 20.76 | Neutral |
| ADX (14) | 18.98 | Neutral |
| Williams %R (14) | -72.81 | Neutral |
| ATR (14) | 19.8 | High Volatility |
| ROC (12) | -8.5 | Sell |
| Stoch RSI (14) | 48.21 | Neutral |
| UO (7,14,28) | 44.11 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 4m - Converted 2,79,000 warrants into 2,79,000 equity shares; Rs.88,40,812.50 received; paid-up capital increased on 07-Mar-2026. | [Board Meeting Outcome for Outcome Of The Board Meeting Held On Saturday, March 07, 2026 4m - Converted 2,79,000 warrants into 2,79,000 equity shares; Rs.88,40,812.50 received; paid-up capital increased on 07-Mar-2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/31a5efc7-9e88-47cd-b636-e30c8bf9b460.pdf) |
| 3m - 2,79,000 warrants converted into equity; Rs.88,40,812.50 received; shares allotted March 7, 2026. | [Announcement under Regulation 30 (LODR)-Conversion of Securities 3m - 2,79,000 warrants converted into equity; Rs.88,40,812.50 received; shares allotted March 7, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/f5ce253b-a007-4f53-b0f0-e5edf93e6e5c.pdf) |
| 27 Jan - Shelter Pharma secured $103,950 export order from Sudan's Taha Drugs for All Vitamins Tablet 3*10 strips, execution within two months. | [Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order 27 Jan - Shelter Pharma secured $103,950 export order from Sudan's Taha Drugs for All Vitamins Tablet 3*10 strips, execution within two months.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/db2a9567-561f-4e4a-a74d-e7186a5d360a.pdf) |
| 27 Apr 2021 - Compliance Certificate certifying maintaining of Physical & Electronic transfer facility with Niche Technologies Private Limited for the Half yearly ended 31st March, 2021 under regulation … | [Compliance Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 27 Apr 2021 - Compliance Certificate certifying maintaining of Physical & Electronic transfer facility with Niche Technologies Private Limited for the Half yearly ended 31st March, 2021 under regulation …](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee9c4dcd-54d5-4bd8-a490-25645a322a6b.pdf) |
| 27 Apr 2021 - Compliance Certificate certifying maintaining of Physical & Electronic transfer facility with Niche Technologies Private Limited for the Half yearly ended 31st March, 2021 under regulation … | [Compliance Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 27 Apr 2021 - Compliance Certificate certifying maintaining of Physical & Electronic transfer facility with Niche Technologies Private Limited for the Half yearly ended 31st March, 2021 under regulation …](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ee9c4dcd-54d5-4bd8-a490-25645a322a6b.pdf) |
| 23 Jan - Shelter Pharma secured $141,600 export order from Taha Drugs (Sudan) for Joemega 3x10 strips; delivery within two months. | [Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order 23 Jan - Shelter Pharma secured $141,600 export order from Taha Drugs (Sudan) for Joemega 3x10 strips; delivery within two months.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/94ad250e-f6cf-482d-828b-9cf8e2fb199f.pdf) |
| 2 Feb - Shelter Pharma launches FitKick Pro pre-workout powder in three flavors, Feb 2, 2026. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 2 Feb - Shelter Pharma launches FitKick Pro pre-workout powder in three flavors, Feb 2, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6f38f0e-a244-4267-9b34-fa05ee341e0d.pdf) |
| 16 Jan - Certificate Under Reqgulation 74(5) of SEBI ( Depositories and Participants) Regulation 2018 for Quarter ended 31st December, 2025 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 16 Jan - Certificate Under Reqgulation 74(5) of SEBI ( Depositories and Participants) Regulation 2018 for Quarter ended 31st December, 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5353f7cb-6966-475d-b437-aa177f2a1a23.pdf) |
| 16 Dec 2025 - Shelter Pharma secured $27,540 order from Sudan’s Taha Drugs for D3 Cure Capsules (3×10), delivery within two months. | [Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order 16 Dec 2025 - Shelter Pharma secured $27,540 order from Sudan’s Taha Drugs for D3 Cure Capsules (3×10), delivery within two months.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ce059110-6d54-4886-81e9-c3c11019566b.pdf) |
| — | [Compliance Under Regulations 40(9) Of SEBI (Listing And Obligation Disclosure Requirements) Regulations, 2015 26 Apr 2021](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=73fff328-4598-419f-a318-4890c8a14419.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/893e85e6-b153-48cc-88f5-dd4ff43805c3.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0ceaf6d3-9fbe-4d1c-97c8-0adb21413c0c.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/506087/67381506087.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/506087/5060870319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/506087/5060870318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/506087/5060870317.pdf) |
| from bse | [Annual Report 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport/506087/5060870316.pdf) |
| from bse | [Annual Report 2015 from bse](https://www.bseindia.com/bseplus/AnnualReport/506087/5060870315.pdf) |
| from bse | [Annual Report 2014 from bse](https://www.bseindia.com/bseplus/AnnualReport/506087/5060870314.pdf) |
| from bse | [Annual Report 2013 from bse](https://www.bseindia.com/bseplus/AnnualReport/506087/5060870313.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:17:20.580Z.